How do you view epcoritamab + R² in an older or frail patient with follicular lymphoma who would otherwise be a candidate for additional treatment after progresion on first line therapy?

Older and frail patients often derive less benefit from repeated chemotherapy as cumulative toxicity becomes increasingly important. ER2 offers the potential for a highly effective chemotherapy-free approach while maintaining an acceptable safety profile, but I think careful patient selection is ess...

It really depends on the fitness of an older patient or the specific comorbidities of a frail patient, along with what their initial treatment was, when they received initial therapy, and what is driving the need for treatment. However, this is a more intense schedule for the first 3 cycles with wee...